Century Sage Scientific Holdings Ltd (1450) AI Stock Analysis

• Market Cap: HK$1.35B
• Dividend Yield: N/A
• Average Volume (3M): 1.96M
• Price to Earnings (P/E): 23.2
• Beta (1Y): 0.35
• Revenue Growth: -1.52%
• EPS Growth: -67.16%
• Country: HK
• Employees: 1,163
• Sector: Technology
• Sector Strength: 88
• Industry: Software - Application
• EPS (TTM): 0.05
• Shares Outstanding: 1,387,203,100
• 10 Day Avg. Volume: 2,198,140
• 30 Day Avg. Volume: 1,964,156
• PEG Ratio: -0.57
• Price to Book (P/B): 3.34
• Price to Sales (P/S): 1.12
• P/FCF Ratio: -30.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.48
• Revenue Forecast (FY): HK$14.52B

• Rating: 64 Neutral
• Price Target: HK$1.00 ▼(-12.28% Downside)

The overall stock score of 64 reflects strong technical momentum and a solid financial position, despite challenges in cash flow and valuation concerns. The absence of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Gross margin strength

A near-48% gross margin indicates durable product-level profitability and likely pricing power or efficient COGS. This margin buffer supports ongoing R&D and commercialization spending, helping sustain operating performance through industry cycles over the next several months.

Balanced capital structure & high ROE

A healthy equity ratio and manageable 0.60 leverage, paired with a 19.5% ROE, signal efficient use of capital and financial resilience. This balance supports investment flexibility and reduces refinancing risk, strengthening the company's ability to execute strategy over the medium term.

Diversified revenue streams

Multiple revenue channels—product sales, partnerships, licensing and services—reduce concentration risk and smooth cash generation. Strategic collaborations and mixed income sources increase chances of sustained commercialization and recurring revenue as the company scales its medical offerings.

Negative Factors

Operating cash flow weakness

Zero operating and free cash flow in 2024 signals limited internal cash generation, constraining reinvestment in R&D or commercial expansion. Over the next 2–6 months this raises liquidity and funding risk, potentially forcing external financing or cutbacks that impair strategic execution.

Net profit margin erosion

A drop from 11.1% to 6.5% net margin indicates rising operating costs or pricing pressure, which reduces retained earnings and the firm's ability to self-fund growth. If persistent, margin erosion undermines long-term profitability and limits resources for strategic initiatives.

Significant EPS contraction

A roughly 67% decline in EPS reflects material earnings deterioration and volatility. Sustained EPS weakness reduces internal funding capacity, may raise cost of capital, and can hinder long-term investment in product development and commercialization, risking slower structural growth.

Century Sage Scientific Holdings Ltd Business Overview & Revenue Model

Company Description

Be Friends Holding Ltd. is an investment company, which engages in the provision of hardware and software all-media application solutions. It operates through the following business segments: New Media Services, Application Solutions, System Maintenance Services, and Sales of Self-Developed Products. The company was founded by Chi Sum Lo in 2007 and is headquartered in Hangzhou, China.

How the Company Makes Money

Century Sage Scientific Holdings Ltd generates revenue through multiple streams, primarily by selling its proprietary medical devices and diagnostic products to hospitals, clinics, and healthcare professionals. The company also engages in research collaborations and partnerships with pharmaceutical firms, which often involve joint development projects that can lead to revenue-sharing agreements or upfront licensing fees. Additionally, the company may derive income from providing consulting services related to its technologies and from grants or funding associated with its research initiatives. Overall, the combination of product sales, strategic partnerships, and service offerings constitutes the core of its revenue model.

Century Sage Scientific Holdings Ltd Financial Statement Overview

Summary

Century Sage Scientific Holdings Ltd exhibits robust revenue growth and a solid balance sheet, underscoring its potential for long-term stability. However, the decline in net profit margin and cash flow generation pose potential risks to financial health. Continued focus on operational efficiency and liquidity management will be crucial for future performance.

Income Statement

The income statement reflects a strong revenue growth trajectory, with total revenue increasing significantly from 2023 to 2024. Gross profit margin is solid at 47.9%, indicating efficient cost management. However, the net profit margin has decreased to 6.5% from 11.1% in the previous year, suggesting higher expenses or lower operational efficiency. The EBIT margin is moderate at 8.5%, showing some profitability challenges.

Balance Sheet

The balance sheet shows a healthy equity ratio of 45.3%, indicating a stable capital structure. The debt-to-equity ratio is moderate at 0.60, reflecting manageable leverage levels. Return on equity is strong at 19.5%, demonstrating efficient use of equity capital. Overall, the balance sheet presents a balanced financial position with no significant red flags.

Cash Flow

The cash flow statement reveals challenges with cash generation, as operating and free cash flows are zero for 2024. This could indicate issues with liquidity or reinvestment capacity. The lack of free cash flow growth and operating cash flow to net income ratio suggest potential cash management issues despite previous years showing positive cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.25B	1.25B	1.07B	425.61M	202.79M	153.31M
Gross Profit	549.39M	599.30M	566.91M	189.80M	60.33M	55.85M
EBITDA	90.77M	119.87M	184.30M	19.76M	-22.52M	-44.96M
Net Income	54.00M	81.71M	119.46M	-9.21M	-61.62M	-97.53M
Balance Sheet
Total Assets	1.01B	923.92M	754.59M	446.91M	422.68M	498.64M
Cash, Cash Equivalents and Short-Term Investments	235.59M	113.32M	149.54M	50.93M	111.06M	12.78M
Total Debt	51.70M	252.83M	168.96M	151.23M	182.62M	182.12M
Total Liabilities	522.86M	510.21M	452.88M	343.92M	334.29M	392.86M
Stockholders Equity	493.30M	418.99M	297.51M	93.30M	65.80M	80.88M
Cash Flow
Free Cash Flow	80.73M	-45.69M	167.14M	-6.90M	7.43M	-2.52M
Operating Cash Flow	90.66M	-27.58M	182.99M	-2.08M	7.81M	-1.61M
Investing Cash Flow	-23.23M	-58.44M	-74.47M	32.34M	4.28M	-3.18M
Financing Cash Flow	-35.38M	52.47M	-10.28M	-34.83M	36.10M	5.00M

Century Sage Scientific Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1450, the sentiment is Negative. The current price of 1.14 is above the 20-day moving average (MA) of 1.04, above the 50-day MA of 1.11, and above the 200-day MA of 1.03, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 29.46 is Positive, neither overbought nor oversold. The STOCH value of 24.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1450.

Century Sage Scientific Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1675	71 Outperform	HK$8.07B	18.52	6.90%	3.47%	-17.90%	56.67%
1450	64 Neutral	HK$1.35B	23.21	11.90%	―	-1.52%	-67.16%
1588	64 Neutral	HK$2.60B	30.86	8.51%	―	12.46%	―
1808	62 Neutral	HK$658.75M	6.16	27.53%	―	421.56%	328.43%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
8083	52 Neutral	HK$4.73B	-51.43	-8.12%	―	3.97%	-211.11%
1782	52 Neutral	HK$3.93B	-49.70	-37.61%	―	-16.86%	-7.51%

Century Sage Scientific Holdings Ltd Corporate Events

Be Friends Holding Reshapes Leadership as Li Liang Succeeds Li Jun as Chairman

Be Friends Holding Limited has announced a leadership reshuffle effective 27 January 2026, with current chairman and executive director Li Jun stepping down from the chairmanship while remaining on the board to focus on driving the group’s intelligent and technological transformation and the development of data-driven AI agents across its operations. Executive director and CEO Li Liang, a former senior executive at New Oriental with extensive management experience and a 6.89% equity stake in the company, will assume the role of chairman, consolidating leadership over strategy, corporate governance and board performance in a move that signals continuity in governance while emphasizing a stronger push toward technology-driven growth.

The most recent analyst rating on (HK:1450) stock is a Buy with a HK$1.00 price target. To see the full list of analyst forecasts on Century Sage Scientific Holdings Ltd stock, see the HK:1450 Stock Forecast page.

Be Friends Holding Announces Board Composition and Committee Roles

Be Friends Holding Limited, a Cayman Islands–incorporated company listed on the Hong Kong Stock Exchange under stock code 1450, has announced the current composition of its board of directors and the allocation of roles across its key governance committees. The company’s board comprises three executive directors and three independent non-executive directors, with Li Liang serving as chairman and chief executive officer, and independent director Kong Hua Wei acting as lead independent non-executive director. The release details the membership and chairmanship of the audit, remuneration, nomination, and investment committees, underscoring the firm’s governance structure and the separation of oversight responsibilities among executive and independent directors, which is relevant for investor assessment of board independence and internal control.

The most recent analyst rating on (HK:1450) stock is a Buy with a HK$1.00 price target. To see the full list of analyst forecasts on Century Sage Scientific Holdings Ltd stock, see the HK:1450 Stock Forecast page.

Be Friends Holding Posts Higher GMV for Q4 and Full Year 2025

Be Friends Holding Limited reported that its gross merchandise volume (GMV) reached approximately RMB6.49 billion in the fourth quarter of 2025, up around 4.34% from the same period in 2024. For the full year 2025, cumulative GMV totaled about RMB16.02 billion, representing a year-on-year increase of roughly 6.23%, signaling steady business expansion for the company’s video-driven e-commerce and omnimedia operations, although the figures are based on unaudited operational data and may not reflect full financial performance.

The most recent analyst rating on (HK:1450) stock is a Buy with a HK$1.50 price target. To see the full list of analyst forecasts on Century Sage Scientific Holdings Ltd stock, see the HK:1450 Stock Forecast page.

Be Friends Holding Limited Passes Key Resolution at EGM

Be Friends Holding Limited, a company incorporated in the Cayman Islands, announced the successful passage of an ordinary resolution at its Extraordinary General Meeting held on 7 November 2025. The resolution, which involved the ratification and approval of an Equity Purchase Agreement and its supplemental agreement, was passed with 100% of the votes cast in favor. This development marks a significant step for the company, potentially impacting its strategic operations and aligning with shareholder interests, as a substantial portion of shareholders abstained from voting due to existing interests.

The most recent analyst rating on (HK:1450) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Century Sage Scientific Holdings Ltd stock, see the HK:1450 Stock Forecast page.